Brian MD - Lucid Diagnostics Chief Officer
| LUCD Stock | USD 1.00 0 0.10% |
Insider
Brian MD is Chief Officer of Lucid Diagnostics
| Age | 59 |
| Address | 360 Madison Avenue, New York, NY, United States, 10017 |
| Phone | 917 813 1828 |
| Web | https://www.luciddx.com |
Lucid Diagnostics Management Efficiency
The company has return on total asset (ROA) of (1.0102) % which means that it has lost $1.0102 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (10.0783) %, meaning that it created substantial loss on money invested by shareholders. Lucid Diagnostics' management efficiency ratios could be used to measure how well Lucid Diagnostics manages its routine affairs as well as how well it operates its assets and liabilities. At present, Lucid Diagnostics' Return On Equity is projected to increase based on the last few years of reporting. At present, Lucid Diagnostics' Intangible Assets are projected to decrease significantly based on the last few years of reporting. The current year's Intangibles To Total Assets is expected to grow to 0.09, whereas Total Assets are forecasted to decline to about 26.8 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| John McKune | Pulmonx Corp | 48 | |
| Jason Edie | Paragon 28 | N/A | |
| Matt Jarboe | Paragon 28 | N/A | |
| Mark Saxton | Neuropace | 59 | |
| Giora MD | Beyond Air | N/A | |
| Erik Mickelson | Paragon 28 | 42 | |
| Steve Deitsch | Paragon 28 | N/A | |
| Lindsey Little | LivaNova PLC | N/A | |
| Brendan Shook | Paragon 28 | N/A | |
| Lee Rosenthal | Paragon 28 | N/A | |
| Douglas Larson | Beyond Air | 54 | |
| Rebecca Doren | Beyond Air | N/A | |
| Sri Radhakrishnan | Pulmonx Corp | N/A | |
| Edward Barger | Beyond Air | N/A | |
| Meghan Scanlon | Paragon 28 | 48 | |
| Lauren Cristina | Pulmonx Corp | N/A | |
| Margaret Carthy | Integer Holdings Corp | 60 | |
| Marco Dolci | LivaNova PLC | 62 | |
| Paul Verrastro | CVRx Inc | 61 | |
| Chi Nguyen | Neuropace | 47 | |
| BA Chemistry | Orthofix Medical | 63 | |
Management Performance
| Return On Equity | -10.08 | ||||
| Return On Asset | -1.01 |
Lucid Diagnostics Leadership Team
Elected by the shareholders, the Lucid Diagnostics' board of directors comprises two types of representatives: Lucid Diagnostics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Lucid. The board's role is to monitor Lucid Diagnostics' management team and ensure that shareholders' interests are well served. Lucid Diagnostics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Lucid Diagnostics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Michael Gordon, General Secretary | ||
| Lishan MD, Chairman CEO | ||
| Joseph MD, Strategic Cofounder | ||
| Michael Parks, Vice Relations | ||
| Adrian Miller, VP Relations | ||
| Amitabh MD, Strategic Cofounder | ||
| Deepika Lakhani, Chief Officer | ||
| Shaun MBA, President COO | ||
| Brian MD, Chief Officer | ||
| Richard Yazbeck, Chief Officer | ||
| Dennis CPA, Chief Officer |
Lucid Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Lucid Diagnostics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -10.08 | ||||
| Return On Asset | -1.01 | ||||
| Operating Margin | (9.98) % | ||||
| Current Valuation | 109.94 M | ||||
| Shares Outstanding | 55.45 M | ||||
| Shares Owned By Insiders | 59.09 % | ||||
| Shares Owned By Institutions | 4.20 % | ||||
| Number Of Shares Shorted | 422.42 K | ||||
| Price To Book | 2.16 X | ||||
| Price To Sales | 13.24 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Lucid Diagnostics is a strong investment it is important to analyze Lucid Diagnostics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Lucid Diagnostics' future performance. For an informed investment choice regarding Lucid Stock, refer to the following important reports:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lucid Diagnostics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. For information on how to trade Lucid Stock refer to our How to Trade Lucid Stock guide.You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lucid Diagnostics. If investors know Lucid will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lucid Diagnostics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.12) | Revenue Per Share 0.09 | Quarterly Revenue Growth 0.497 | Return On Assets (1.01) | Return On Equity (10.08) |
The market value of Lucid Diagnostics is measured differently than its book value, which is the value of Lucid that is recorded on the company's balance sheet. Investors also form their own opinion of Lucid Diagnostics' value that differs from its market value or its book value, called intrinsic value, which is Lucid Diagnostics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lucid Diagnostics' market value can be influenced by many factors that don't directly affect Lucid Diagnostics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lucid Diagnostics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Lucid Diagnostics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lucid Diagnostics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.